Evofem Biosciences (EVFM) has issued an update.
Evofem Biosciences, Inc. has struck a landmark deal granting Pharma 1 exclusive rights to develop and sell its product in several Middle Eastern countries, with the aim to secure local governmental approvals for commercial launch. Additionally, the company has completed a strategic financing move by selling preferred stock to Aditxt, Inc. and established a Registration Rights Agreement to facilitate the future resale of common stock. These agreements represent significant steps in expanding Evofem’s global footprint and securing its financial growth.
Learn more about EVFM stock on TipRanks’ Stock Analysis page.
